These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
27. [Experience in using the new antiemetic preparation Navoban in hemoblastosis patients]. Demidova IA Ter Arkh; 1993; 65(10):61-2. PubMed ID: 8296237 [No Abstract] [Full Text] [Related]
28. [Vomiting: causes and therapy]. Neiger R Schweiz Arch Tierheilkd; 1996; 138(9):421-8. PubMed ID: 9005542 [TBL] [Abstract][Full Text] [Related]
29. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis. Neufeld SM; Newburn-Cook CV J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095 [TBL] [Abstract][Full Text] [Related]
30. [Physiopathology, risk factors and therapy. Postoperative Nausea and vomiting (PONV)]. Wurglics M; Spiegl F Pharm Unserer Zeit; 2007; 36(5):368-72. PubMed ID: 17722164 [No Abstract] [Full Text] [Related]
31. New directions for anti-emetic research. Smyth JF Ann Oncol; 1994 Sep; 5(7):569-70. PubMed ID: 7993828 [No Abstract] [Full Text] [Related]
32. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762 [TBL] [Abstract][Full Text] [Related]
33. [The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting]. Kreutz S Pharm Unserer Zeit; 2007; 36(5):389-92. PubMed ID: 17722146 [No Abstract] [Full Text] [Related]
34. [Glucocorticoids: a two-edged sword in tumor therapy?]. Kelm-Kahl I Dtsch Med Wochenschr; 2003 Aug; 128(33):1697. PubMed ID: 12968629 [No Abstract] [Full Text] [Related]
35. [New treatment of vomiting in infants]. Formstecher P; Fontaine G Lille Med; 1976 Jan; 21(1 suppl 1):17-9. PubMed ID: 1256227 [No Abstract] [Full Text] [Related]
36. Concordance between substance P levels and antiemetic guidelines. Higa GM; Auber ML; Altaha R; Kurian S; Hobbs G J Support Oncol; 2009; 7(4):138-42. PubMed ID: 19731580 [TBL] [Abstract][Full Text] [Related]
37. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting? Sarcev T; Secen N; Zaric B; Milovancev A J BUON; 2008; 13(3):333-9. PubMed ID: 18979546 [TBL] [Abstract][Full Text] [Related]
38. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. Hartvig P J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570 [No Abstract] [Full Text] [Related]
39. [Pharmacologic and clinical interest of serotonergic receptors of the gastrointestinal tract]. García-Zaragozá E; Moreno L; Esplugues JV Gastroenterol Hepatol; 2001 Feb; 24(2):70-6. PubMed ID: 11247293 [No Abstract] [Full Text] [Related]
40. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Oo TH; Hesketh PJ Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]